Editor's Note: Green and red arrows refer to intraday stock price movement.
NEW YORK (TheStreet) -- CHANGE IN RATINGS
AK Steel (AKS) downgraded at Goldman from Buy to Neutral. Company is facing higher input costs.
The Buckle (BKE) upgraded at Goldman from Sell to Neutral. $28 price target. Fashion cycle is easing for the company.Corrections Corp of America (CXW) downgraded at Barclays to Equal Weight from Overweight. Minimal margin improvement opportunities. Price target raised by a dollar to $28. Ruddick (RDK) downgraded at BMO from Outperform to Market Perform. Valuation call, based on a $38 price target. Research in Motion (RIMM) downgraded at Kaufman from Buy to Hold. $60 price target. Company is facing increased competition. Rovi (ROVI) rated new Outperform at BMO. Coverage of ROVI was started with an Outperform rating. $60 price target. Growth should accelerate as its content and reach expands. Reliance Steel (RS) upgraded at Goldman from Neutral to Buy. Company has exposure to growth in the aerospace and energy markets. Seattle Genetics (SGEN) rated new Overweight at Piper Jaffray. $20 price target. Company is on the verge of bringing its first drug to market. Symantec (SYMC) upgraded at ISI from Hold to Buy. $22 price target. Company is executing better and is a potential takeover target. Taleo (TLEO) downgraded at Credit Suisse to Neutral from Outperform. Valuation call. Maintain $30 price target. Trinity Industries (TRN) rated new Outperform at Wells Fargo. Rail supply industry appears to be at the beginning of a multi-year recovery. Viropharma (VPHM) rated new Overweight at Piper Jaffray. $20 price target. HAE drug should ultimately be able to generate $500 million of annual U.S. sales.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV